{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:10:28Z","timestamp":1784301028969,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,2,3]],"date-time":"2019-02-03T00:00:00Z","timestamp":1549152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To demonstrate the noninferiority of extrafine beclomethasone\/formoterol fumarate (BDP\/FF) dry powder inhaler (DPI) <jats:italic>vs<\/jats:italic>. extrafine BDP\/FF pressurized metered dose inhaler (pMDI; Foster\u00ae 100\/6\u00a0\u03bcg NEXThaler and pMDI, respectively) in the onset of reliever effect after methacholine induced bronchospasm in asthmatic patients, evaluated in terms of forced expiratory volume in 1\u00a0s (FEV<jats:sub>1<\/jats:sub>) at 5\u00a0min postdose. The DPI provides an alternative device option for patients who cannot use a pMDI properly during an acute asthma attack.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixty\u2010five patients received one inhalation of BDP\/FF DPI, BDP\/FF pMDI or placebo after methacholine challenge, according to a double\u2010blind, double\u2010dummy, cross\u2010over design. Lung function and Borg dyspnoea score were assessed up to 30\u00a0min postdose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>FEV<jats:sub>1<\/jats:sub> adjusted mean difference between BDP\/FF DPI and BDP\/FF pMDI at 5\u00a0min postdose was 2\u00a0ml (95% confidence interval: \u20130.060; 0.065). A similar result was observed at the other time points. Median time to 85% recovery in FEV<jats:sub>1<\/jats:sub> was 8\u00a0min for BDP\/FF DPI, 7.5\u00a0min for BDP\/FF pMDI and 28\u00a0min for placebo (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.554 DPI <jats:italic>vs<\/jats:italic>. pMDI). The Borg score improved after treatment with both BDP\/FF DPI and pMDI and the effect was greater than after placebo. Median time to reach 50% recovery was 4.2\u00a0min for BDP\/FF DPI, 4.0\u00a0min for BDP\/FF pMDI and 10.0\u00a0min for placebo (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.609 DPI <jats:italic>vs<\/jats:italic>. pMDI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Extrafine Foster\u00ae NEXThaler, a flow\u2010independent DPI, is comparable to extrafine Foster\u00ae pMDI when administered as reliever therapy after methacholine challenge, thus supporting the maintenance and reliever therapy approach also with Foster\u00ae NEXThaler.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13847","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T15:59:26Z","timestamp":1545839966000},"page":"729-736","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of the effect of beclometasone\/formoterol in asthma patients after methacholine\u2010induced bronchoconstriction: A noninferiority study using metered dose <i>vs<\/i>. dry powder inhaler"],"prefix":"10.1111","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8918-7075","authenticated-orcid":false,"given":"Dave","family":"Singh","sequence":"first","affiliation":[{"name":"Medicines Evaluation Unit University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Hammersmith Medicines Research ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leaker","sequence":"additional","affiliation":[{"name":"Respiratory Clinical Trials ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-4184","authenticated-orcid":false,"given":"Massimo","family":"Corradi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery University of Parma  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-9807","authenticated-orcid":false,"given":"Sunny","family":"Jabbal","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Research  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8625-3142","authenticated-orcid":false,"given":"Sara","family":"Collarini","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici SpA  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mongelli","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici SpA  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Santoro","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici SpA  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-788X","authenticated-orcid":false,"given":"Annalisa","family":"Piccinno","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici SpA  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Biondaro","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici SpA  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lipworth","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Research  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,2,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40413-017-0144-5"},{"key":"e_1_2_8_3_1","unstructured":"GINA.Global strategy for asthma management and prevention (GINA 2017). Glob Initiat Asthma2017;147."},{"key":"e_1_2_8_4_1","first-page":"CD008418","article-title":"Formoterol versus short\u2010acting beta\u2010agonists as relief medication for adults and children with asthma","volume":"2010","author":"Welsh EJ","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.9811100"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70012-2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2012.07.004"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2014.07.006"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425240802637862"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2014.928282"},{"key":"e_1_2_8_11_1","first-page":"A1931","article-title":"Measurement of the inhalation profile through a novel dry powder inhaler (NEXThaler) in asthmatic patients using acoustic monitoring","volume":"187","author":"Scuri M","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"e_1_2_8_13_1","first-page":"309","article-title":"American Thoracic Society guidelines for methacholine and exercise challenge testing \u20131999","volume":"161","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0099-1767(00)90093-X"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035205"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.11051086"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1006\/pulp.1996.0031"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.13e10.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(98)90140-8"},{"issue":"58","key":"e_1_2_8_20_1","article-title":"Inspiratory flow resistance of marketed dry powder inhalers (DPI)","volume":"44","author":"Kr\u00fcger P","year":"2014","journal-title":"Eur Respir J"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2015.1220"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13847","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13847","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13847","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:19:53Z","timestamp":1694409593000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,3]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/bcp.13847"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13847","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,3]]}}}